Tower Research Capital LLC (Trc) Galecto, Inc. Transaction History

Tower Research Capital LLC (Trc)

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$0.47 - $0.76 $1,427 - $2,308	3,038 Added 634.24%	3,517 $1,000
Q1 2024 May 15, 2024	SELL	$0.6 - $0.89 $4,425 - $6,564	-7,376 Reduced 93.9%	479 $0
Q4 2023 Feb 13, 2024	SELL	$0.52 - $0.78 $81 - $121	-156 Reduced 1.95%	7,855 $5,000
Q3 2023 Nov 14, 2023	BUY	$0.56 - $3.17 $3,335 - $18,880	5,956 Added 289.83%	8,011 $5,000
Q2 2023 Aug 14, 2023	SELL	$1.68 - $2.84 $2,499 - $4,225	-1,488 Reduced 42.0%	2,055 $5,000
Q1 2023 May 09, 2023	SELL	$1.21 - $2.86 $4,969 - $11,746	-4,107 Reduced 53.69%	3,543 $7,000
Q4 2022 Feb 10, 2023	BUY	$1.06 - $58.5 $4,913 - $271,147	4,635 Added 153.73%	7,650 $9,000
Q3 2022 Nov 10, 2022	BUY	$1.59 - $60.0 $672 - $25,380	423 Added 16.32%	3,015 $6,000
Q2 2022 Aug 15, 2022	BUY	$1.22 - $2.74 $2,666 - $5,989	2,186 Added 538.42%	2,592 $4,000
Q1 2022 May 12, 2022	BUY	$1.72 - $3.31 $698 - $1,343	406 New	406 $1,000
Q4 2021 Feb 14, 2022	SELL	$2.3 - $3.58 $30,196 - $47,001	-13,129 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$3.59 - $5.0 $18,822 - $26,215	5,243 Added 66.48%	13,129 $47,000
Q2 2021 Aug 16, 2021	BUY	$4.63 - $8.0 $36,512 - $63,088	7,886 New	7,886 $40,000

21.2K

Ticker GLTO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,395,700
Market Cap $119M
Description
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clini...

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.